摘要
目的分析经肝动脉化疗栓塞术(TACE)联合单药口服希罗达治疗结直肠癌肝转移的疗效及不良反应。方法一线化疗失败的非手术结直肠癌肝转移患者30例,随机均分为两组:试验组经TACE 3周后予以希罗达口服化疗,停药1周后评价疗效;对照组给予标准mFOLFOX6/FOLFIRI方案化疗,2个周期后予以评价疗效。比较两组近期疗效和不良反应。结果两组均无完全缓解病例,试验组部分缓解(PR)4例,疾病稳定(SD)6例、疾病进展(PD)5例,对照组PR 3例、SD 6例、PD 6例。试验组年平均住院日少于对照组[(56.27±2.19)d vs.(85.33±2.52)d](P<0.05);试验组肝功能损害、发热、腹痛和手足综合征发生比例高于对照组(P<0.05),但白细胞及血小板减少发生比例低于对照组(P<0.05)。结论 TACE联合希罗达治疗结直肠癌肝转移患者有一定疗效,能缩短年均住院时间,不良反应少。
Objective To investigate the efficacy and adverse effects of transcatheter arterial chemoembolization（TACE）combined with single-agent xeloda（capecitabine）in the treatment of colorectal cancer with hepatic metastases.Methods Thirty patients with hepatic metastases of inoperable colorectal cancer,who failled to the first-line chemotherapy,were equally randomized into two groups of A（treated with TACE combined with oral xeloda 1250mg/m^2 bid.for 14days）and B（treated with conventional regimen of chemotherapy with mFOLFOX6/FOLFIRI）.The short-term efficacy and adverse effects were compared between two groups.Results There was no case with complete remission in both groups.Partial remission was seen in 4cases,stable disease was seen in6 cases,progress disease in 5cases in group A.Group B had partial remission in 3cases,stable disease in 6cases and progress disease in 6cases.The averaged hospital stay per year was less in group A than that in group B[（56.27±2.19）d vs.（85.33±2.52）d]（P〈0.05）.The incidences of hepatic dysfunction,fever,abdominal pain and hand-foot syndrome were higher,but WBC and Plt decreases were less,in group A than those in group B（P〈0.05）.Conclusion TACE combined with single-agent xeloda has a certain efficacy as the second-line remedial regimen for the treatment of patients with hepatic metastases of inoperable colorectal cancer with less averaged hospital stay per year and adverse effects.
出处
《江苏医药》
CAS
2016年第9期1031-1033,共3页
Jiangsu Medical Journal
关键词
结直肠癌肝转移
经肝动脉化疗栓塞术
希罗达
Hepatic metastases of colorectal cancer
Transcatheter arterial chemoembolization
Xeloda
